The GLP-1 trend isn't slowing down. But your spend can
Embla gives health plans a clinically validated way to cover GLP-1s with predictable costs. Behavior-led care that keeps doses low and taper rates high.
GLP-1 demand is here, and growing
Why conventional GLP-1 coverage falls short
Full-dose prescriptions can quickly overwhelm your medical trend.
Without coaching, members often regain weight or stop treatment early.
Most solutions don’t taper, driving long-term costs and dependency.
A proven, cost-controlled GLP-1 program
We combine low-dose GLP-1s with ACT-based coaching and structured tapering, so members reach meaningful results with less medication.
Boosted engagement
1:1 coaching, digital tracking, and flexible care plan, without extra work for your team.
Improved outcomes
Members see improvements in weight, energy, mental health, and metabolic risk.
Lower claims
Our low-dose approach reduces both pharmacy and chronic condition costs.
A strategic edge
Stand out with a high-demand solution that meets member needs and controls trend, with one fixed fee per engaged member, medication included.
Real-world results.
Real-world savings.
We keep members on the lowest effective dose, which cuts GLP-1 costs by up to half.
Over 64 weeks in the TRIM study (n=2,694), using less than half the standard maximum dose.
Backed by data: lower A1c, blood pressure, cholesterol, and long-term obesity-related costs.
Programs that fit every population
Metabolic care built around behavior change, medication when needed, and long-term support.
Behavior-first metabolic care
GLP-1 + behavior change
Weight maintenance support
Easy to offer, built to scale
Getting started with Embla is fast and seamless. We handle everything so you don’t have to.
01. Connect with us
We’ll schedule your launch date and get aligned on goals and participants.
02. We take care of setup
Our team handles onboarding, communications, and custom roll out materials. No integration or extra work on your end.
03. Start changing lives
Most plans go live 4 to 8 weeks after kickoff. We’ll keep you updated on engagement, results, and health improvements.
Backed by real-world data from 2,694 members
Our TRIM study, published in Diabetes, Obesity and Metabolism (2025), found:
16.7% average weight loss over 64 weeks
Less than half the standard maximum semaglutide dose
55% less GLP-1 medication
Similar outcomes across BMI classes
Easy to launch. Easy to love.
Embla is fully managed and plug-and-play. No complicated onboarding. No surprises.
Ready to take control of GLP-1 spend?
Let’s talk about how Embla can help you reduce GLP-1 spend and raise the standard of care.